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A 23 amino acid synthetic peptide fragment of atrial natriuretic factor (ANF) stimulated guanylate cyclase 
activity in isolated human glomeruli in a concentration- and time-dependent manner. ANF activated parti- 
culate guanylate cyclase whereas it had no effect on soluble guanylate cyclase. These results demonstrate 
that the glomerulus i a target structure for ANF in humans. They also suggest that ANF-induced increase 
in glomerular fhration rate is due to a direct effect of this peptide on the glomerular cells mediated by acti- 
vation of glomerular guanylate cyclase. 
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1. I~RODUCTION 
It has become increasingly evident in the last 10 
years that many extrarenal and renal humoral 
agents regulate the glomerular filtration rate 
through a change in the glomerular coefficient of 
~tra~ltration, luf [l]. All the agents tested pro- 
duced a decrease inKf either directly as angiotensin 
II and arginine vasopressin or indirectly as 
parathyroid hormone and prostaglandins via 
stimulation of glomerular adenylate cyclase and 
cyclic AMP-induced local synthesis of renin and 
angiotensin IX f2]. Reduction of Kf results in the 
decrease of glomerular filtration rate (GFR). In 
contrast with these hormones or mediators, atria1 
natriuretic factor (ANF) produces an increase of 
GFR in several animal species [3-51. This peptide 
has also been demonstrated as vasodilatory in vitro 
[6] and it has been suggested that the relaxant ef- 
fect of ANF may be mediated via increased tissue 
levels of cyclic GMP [7]. Studies in humans are 
scarce and provide no information on the effect of 
ANF on GFR [8]. Because of the limitations 
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of in 
vivo studies particul~ to humans we investigated 
the effects of ANF on guanylate cyclase (GTP 
pyrophosphate (cyclizing), EC 4.6.1.2) in human 
glomeruli in vitro. 
2. MATERIALS AND METHODS 
Synthetic rat ANF (atriopeptin II), 23 amino 
acids, was donated by Ciba-Geigy (Basel, Switzer- 
land). The following reagents and radiochemicals 
were also used: GTP, cyclic GMP, creatine kinase, 
phosphocreatine (disodium salt) from Boehringer 
(Mannheim, FRG); papaverine and sodium nitro- 
prusside from Sigma (St. Louis, MO); cyclic 
[3H]GMP (ammonium salt, 15 Ci/mmol) and 
[u-~*P]GTP (sodium salt, 600 Ci/mmol) from 
New England Nuclear (Dreieich, FRG). 
Glomeruli were prepared as described [9]. 
Human renal tissue was obtained from cadaver 
kidneys judged to be unsuitable for transplanta- 
tion (2 cases) or from the normal cortex of kidneys 
surgically removed for malignant umors (2 cases). 
Isolated glomeruli were frozen in liquid nitrogen 
and stored until assayed (1-5 weeks). To separate 
the particulate and the soluble guanylate cyclase, 
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glomeruli were homogenized using a Potter- 
Elvehjem apparatus. The particulate and soluble 
fractions were obtained by high-speed centrifuga- 
tion (100008 x g for 60 min) of the homogenate. 
Clomerular proteins were determined according to 
[w. 
Guanylate cyclase activity was assayed as 
described in [ 1 l] with minor modifications. The in- 
cubation medium (final volume, 100 ~1) contained 
20 mM Tris-HCl (pH 7.5), 5.5 mM MnC12, 5 mM 
MgC12, 0.1 mg/ml BSA, 0.25 mM papaverine, 
10 mM creatine phosphate, 1.2 mg/ml creatine 
kinase, 0.5 mM GTP, 2.5 mM cyclic GMP and 
0.1 &i [u-~~P]GTP. The stimulator agents tested 
were diluted in 10~1 water. Isolated glomeruli or 
glomerul~ fractions (0.2-0.8 mg protein/ml) 
were added at time zero and the incubation was 
carried out for 10 min at 37’C. The reaction was 
stopped by addition of 20 /cl of a solution contain- 
ing 100 mM EDTA (sodium salt) and 30 nCi cyclic 
[3H]GMP followed by immersion in boiling water 
for 3 min. Cyclic GMP was separated by suc- 
cessive filtrations on Dowex AG 50 WX4 (Biorad, 
Richmond, CA) and aluminium oxide (M. Woelm, 
Eschwege, FRG) columns. 3H and 32P radioac- 
tivities were determined by scintillation under ap- 
propriate conditions for discrimination between 
both isotopes. Guanylate cyclase activity was ex- 
pressed as pmol of cyclic GMP formed/IO min per 
pg glomerular protein. 
3. RESULTS 
Guanylate cyclase activity in human glomeruli 
was 0.56 r~; 0.06 and 1.25 f 0.45 pmol. 10 min-’ . 
fk-’ under basal conditions and in the presence of 
0.1 mM sodium ~troprusside, respectively (means 
f SE from 11 individu~ glomerular preparations). 
The latter agent was tested as a well-known 
activator of the enzyme devoid of tissue specificity 
[ 121. Because of the absence of major individual 
differences between the 4 human kidneys utilized 
we pooled the results from the glomerular prepara- 
tions irrespective of the original kidney. 
Incubation of isolated glomeruli with ANF 
resulted in an increase in glomerular guanylate 
cyclase activity. The time course of activation 
(fig.1) shows that the maximal effect of ANF on 
cyclic GMP production occurred at 10 min and 
Fig. 1. Formation of cyclic GMP as a function of time in 
human glomeruli under basal conditions (o--+) and in 
the presence of 0.1 ,uM ANF (w). Each point 
represents he mean and each vertical bar twice the SE 
of 4 individual experiments (3 values for each 
experiment). 
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Fig.2. Effect of ANF concentration  guanylate cyclase 
activity present in whole human glomeruli. Bach point 
represents he mean and each vertical bar twice the SE 
of 4 experiments (3 values for each experiment). The 
dotted line indicates the concentration of ANF 
corresponding to 50% of maximal stimulation. 
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Fig.3. Effect of ANF concentration  guanylate cyclase activity present in the particulate fraction (left) and the soluble 
fraction (right) of homogenized human glomeruli. Each point represents the mean and each vertical bar twice the SE 
of 3 experiments (3 values for each experiment). The dotted line indicates the concentration of ANF corresponding to 
50% of maximal stimulation in the particulate fraction. 
persisted at 15 min. A maximum stimulation of 
3-4-times the basal value was observed at concen- 
trations of l-10 pM. The lowest concentration of 
ANF at which a significant response was first ob- 
tained (threshold dose) was 0.05 PM and the con- 
centration corresponding to 50% of the maximum 
stimulation (ECXJ) was 0.25 PM (fig.2). Guanylate 
cyclase activity was linearly correlated with the 
glomerular concentration of protein between 0.2 
and 0.8 mg/ml both under basal conditions and in 
the presence of 0.1 pM ANF (r = 0.93 for 11 
couples of values). The slope of the regression line 
obtained with ANF (1.23 pmol. 10 min-’ .gg-‘) 
was close to the value of guanylate cyclase activity 
observed at an identical concentration. 
ANF stimulated guanylate cyclase activity in the 
glomerular particulate fraction but had no effect 
on the soluble enzyme (fig.3). The dose-response 
of the particulate guanylate cyclase to ANF was 
similar to that observed with whole glomeruli. 
Maximum stimulation (3.8-times the basal value) 
occurred at 10pM. The threshold and EC50 were 
0.05 and 0.4 FM, respectively. 
10 
4. DISCUSSION 
These findings indicate for the first time that 
ANF stimulates particulate guanylate cyclase in a 
concentration-dependent fashion in human 
isolated glomeruli. Guanylate cyclase activity has 
been demonstrated in rabbit and rat glomeruli 
[ 13,141. Glomeruli contain a much higher 
guanylate cyclase activity than tubules if both are 
isolated simultaneously from the same animal. 
Torres et al. [15] have also shown that glomeruli 
have. a higher content of immunoreactive cyclic 
GMP than tubules. The role of cyclic GMP in the 
regulation of GFR has been studied essentially by 
determining variation of the intracellular level 
of this cyclic nucleotide. Carbamylcholine, a 
cholinergic analogue, and to a lesser degree, 
histamine and serotonin produced an increase in 
glomerular cyclic GMP [15,16]. However, little is 
known on the regulation of glomerular guanylate 
cyclase activity. ANF produced an increase in the 
tissue levels of cyclic GMP in rat kidneys and aor- 
tas [17] and activated guanylate cyclase activity in 
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rabbit aortas [7]. We show in this study that it also 
stimulates guanylate cyclase activity in human 
isolated glomeruli over a similar range of concen- 
trations. The threshold dose (0.05 FM) cor- 
responds approximately to the expected initial 
plasma concentration obtained after administra- 
tion of an intravenous bolus of 1OOpg ANF in 
adult humans, if we consider that ANF is 
distributed in the plasma volume. Under such con- 
ditions, Richards et al. [8] observed a clear increase 
in urine volume and urinary sodium excretion. As 
in the other preparations, ANF had a specific ef- 
fect on particulate compared to soluble guanylate 
cyclase. It is well documented that cyclic GMP for- 
mation is stimulated by hormones only in intact 
cells supporting the view that guanylate cyclase ac- 
tivation is an event relatively distal to hormone- 
receptor interaction with probably increases in 
cytosolic calcium or oxygen reactive species as 
intermediary steps. In contrast, sodium 
nitroprusside and sodium azide have the capacity 
to stimulate cyclic GMP production both in 
broken and intact cells through the soluble form of 
guanylate cyclase [ 121. ANF is thus particular since 
it stimulates guanylate cyclase activity in’s cell-free 
system similarly to what occurs for the hormones 
linked to adenylate cyclase. This may be due to the 
fact that ANF like the peptide hormones in 
general, binds to membrane receptors [18] which 
must be in close vicinity with the enzyme they 
regulate. 
This study demonstrates that the human 
glomerulus is a target structure for ANF and that 
cyclic GMP is the secondary messenger. It is likely 
that the increase of this nucleotide within the 
glomeruli in response to ANF is involved in the 
relaxation of the glomerular mesangial cells which 
show characteristics of modified smooth-muscle 
cells and contract upon addition of ~~otensin II 
and ar~inine-vasopressin [ 191. Relaxation of the 
mesangial cells may result in the increase of the 
filtration surface and thus of Kr. ANF may also in- 
hibit the effects of the vasoconstrictor hormones 
on mesangial cell contractility in accordance with 
the findings reported using isolated perfused 
kidneys [20]. Thus, the stimulation of GFR by 
ANF appears to be the consequence of a direct ef- 
fect of this peptide on the glomerular cells 
mediated by activation of the glomerular guanylate 
cyclase. 
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